Successful Use of COVID-19 Convalescent Plasma in a Patient Recently Treated for Follicular Lymphoma
Journal Article - Open Access
USAF HOSPITAL KEESLER AFB MS KEESLER AFB United States
Pagination or Media Count:
Coronavirus disease 2019 COVID-19 has swept the globe and poses unique treatment challenges for immunocompromised patients with hematologic malignancies. Here, we present the case of a 54-year-old man with follicular lymphoma, recently completing treatment with maintenance rituximab, who endured a protracted course of COVID-19. The patients case was complicated by evolving hypoxic respiratory failure, marked lymphopenia, and hypogammaglobulinemia, which ultimately led to treatment with COVID-19 convalescent plasma, resulting in clinical improvement. Presently, there is no definitive data on the efficacy ofCOVID-19 convalescent plasma in patients withCOVID-19 however, many trials are ongoing. We propose that this may be an effective treatment inpatients treated for lymphoma with subsequent lymphopenia and hypogammaglobulinemia.
- Medicine and Medical Research